title: Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.
authors.affiliation: Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "L. and A. Seràgnoli", St Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Polverelli
authors.forename: L
authors.initials: L
authors.lastname: Catani
authors.forename: N
authors.initials: N
authors.lastname: Vianelli
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: F
authors.initials: F
authors.lastname: Palandri
mesh_terms: D000986:Antisickling Agents / Q000008:administration & dosage*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010976:Platelet Count; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines; D011759:Pyrrolidines; D013163:Splenomegaly / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D013449:Sulfonamides; D013922:Thrombocytosis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D000096926:Benzenesulfonamides
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D011759:Pyrrolidines; D013449:Sulfonamides; C528327:fedratinib; D000096926:Benzenesulfonamides; C540383:ruxolitinib